- We need more evidence on plasma therapy to conclude anything: Dr Guleria
- Current evidence suggests that convalescent plasma is safe: Dr Guleria
- Plasma therapy is not very effective and should be used prudently: Dr Guler
New Delhi: The trial conducted by All India Institute of Medical Sciences (AIIMS) for convalescent plasma therapy on COVID-19 patients did not show much clinical benefit in reducing fatality risk caused due to the virus. “These are initial analyses. There were two groups of 15 patients each on whom a randomised control trial was done to know the effectiveness of plasma therapy. One group received standard treatment protocol while the other group received convalescent plasma therapy along with standard treatment. It was noted that mortality was similar in both the groups with no much clinical benefits to the patients,” Dr Randeep Guleria, Director at AIIMS told ANI.
It is also important to note that we need more evidence on it to conclude anything. Current evidence suggests that convalescent plasma is safe, does not cause any harm to a patient. But at the same time, it (plasma therapy) is not very effective and hence should be used prudently, Dr Guleria further said.
It may be noted that the Union Health Ministry in its clinical management protocol for COVID19 patients has described the use of convalescent plasma therapy as one of the investigational therapies.
The treatment protocol states that convalescent plasma therapy may be considered in patients with the moderate disease who are not improving (oxygen requirement is progressively increasing) despite the use of steroids.
The dose for convalescent plasma can be variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hours).
There are special prerequisites while considering convalescent plasma. It includes ABO compatibility and cross-matching of the donor plasma. Recipients should be closely monitored for several hours post-transfusion for any transfusion related adverse events. However, the use of convalescent plasma should be avoided in patients with IgA deficiency or immunoglobulin allergy, read clinical guidelines.
Meanwhile, the Indian Council of Medical Research (ICMR) is also conducting trials to evaluate the efficacy of plasma therapy, however, results have not been published yet.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene.